Navigation Links
A new drug reduces heart damage
Date:3/10/2013

This press release is available in French.

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise.

"Inclacumab could indeed become an integral part of the therapeutic arsenal of modern cardiology if we can reproduce these results in subsequent studies. We could use the drug for a broader patient population, or for all patients who present with a heart attack, but this will require further study," explained Dr. Tardif, lead investigator of the study and also professor of Medicine at the University of Montreal.

Reducing the risk of complications after angioplasty to treat heart attack

Each year, approximately 35,000 coronary artery angioplasty procedures are conducted in Canada and more than 1 million are conducted in the United States to treat atherosclerosis. This condition occurs when the arteries are obstructed with deposits of fat (cholesterol), calcium and cellular waste. Over time, the arteries lose their elasticity and narrow, which slows down or blocks blood flow. Because of the resulting complications (angina, heart attack, stroke, etc.), patients may ultimately need an angioplasty, which is a percutaneous intervention that dilates the narrowed artery to re-establish blood flow. However, heart tissue can become damaged during an angioplasty, and an inflammatory cascade can lead to other complications.

A single dose may provide benefits

For this clinical study, Dr. Tardif and his team compared the effects of a single dose of this new anti-inflammatory drug with placebo. Inclacumab is an antibody that blocks P-selectin, a molecule that drives inflammation and plays an important role in vascular disease.

To study the effects of the drug, Dr. Tardif and his team administered a single dose of inclacumab and then measured the subjects' levels of troponin I, which is a marker used clinically to diagnose heart attack. They found that inclacumab reduced troponin l levels by 24 %. "It is very exciting to discover that a single dose of inclacumab can provide benefits," stressed Dr. Tardif. The trial involved 530 patients with myocardial infarction whose median age was 61 and 78.9 % of whom were men. Patients were randomized to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg, or placebo 1 to 24 hours before angioplasty. Markers for heart damage were then measured at 8, 16 and 24 hours after angioplasty.

On Sunday March 10, Dr. Tardif will present the results of the SELECT-ACS, supported by Roche, or "Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial" at the 62nd Annual Scientific Session of the American College of Cardiology. ACC.13 is the premier cardiovascular medical meeting in the United States that brings together cardiologists and cardiovascular specialists to further advances in cardiovascular medicine.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related medicine news :

1. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
2. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. NIH study finds sigmoidoscopy reduces colorectal cancer rates
5. Surgical removal of abdominal fat reduces skin cancer in mice
6. Long-term ICS use reduces pleural effusion in patients with CAP
7. Regional anesthesia reduces complications and death for hip fracture patients
8. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
9. Single embryo transfer reduces the risk of perinatal mortality in IVF
10. HPV vaccine reduces infection, even in unvaccinated
11. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... Afrimesure specializes in providing clients with ideal ... and HVAC facilities. Their knowledgeable staff also takes care of the installation, IQ/OQ/PQ ... offers a variety of MadgeTech systems available for sterilization and temperature monitoring, including ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering ... and Prescription Drug survey , an employee benefits survey measuring how ... in December 2015, indicates that employers are turning to consumer directed health care ...
(Date:5/25/2016)... ... May 25, 2016 , ... For more than fifty years, we've suffered whiplash as each ... diets to conform to the latest nutritional advice – advice that was supposed to keep ... than 2 in 3 American adults are considered to be overweight and more than 1 ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, a leading ... their clients' employee participation for their wellness initiatives. BeniComp clients experience nearly ... health plan with outcome-based deductible incentives. As a result, BeniComp clients have been ...
(Date:5/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... as the Medical Director of its new DeSoto facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
Breaking Medicine Technology: